Search Results
28 Results Found for “Antithrombotic therapy”
Late-breaking clinical research will once again be a major focus at ESC Congress 2026, taking place in Munich, Germany, from August 28–31. This year, a record 59 trials have been selected for presentation across 12 Hot Line sessions, spanning new pharmacological approaches, diagnostic strategies, devices, imaging and digital technologies.
After decades of debate, patent foramen ovale (PFO) closure is now a well-established strategy to reduce recurrent stroke in patients aged 18–60 years who have had a PFO-associated stroke.1 Patients who underwent PFO closure continue to have a higher stroke risk ...
At EHRA 2026, late-breaking trials across ablation, devices, and drug therapy signal major shifts in arrhythmia management, highlighting both rapid innovation and key unanswered questions. We spoke to Prof Jose Luis Merino for his highlights.
Presented at EHRA 2026 by Dr David Birnie, the OCEAN trial reveals low, brief atrial fibrillation recurrence rates after successful ablation - findings that may support selective anticoagulation discontinuation while reinforcing the need for ongoing follow-up.
The ESC Congress 2025 congress was an important meeting for clinical practice guidance in cardiology, with several major societies releasing long-awaited updates. As always, clinical practice guidelines remain central to cardiology, ensuring that the latest trial data and real-world evidence are rapidly translated into consistent, evidence-based patient care. This year’s congress saw the unveiling of important new documents across prevention, acute care and long-term management, equipping cardiologists with refined decision pathways, updated risk-stratification tools and clearer benchmarks to optimise patient outcomes.
New joint guidelines from the AHA/ACC have been released for the management of lower extremity peripheral artery disease and have been published simultaneously in Circulation and the Journal of the American College of Cardiology.
Clinically relevant tricuspid regurgitation (TR) is a common disorder, affecting approximately 4% of people 75 years of age or older.1 If left untreated, severe TR results in volume overload and right ventricular remodelling. This eventually leads to symptomatic right-sided heart failure, along ...
A significant proportion of patients with atrial fibrillation (AF) who have a high stroke risk are currently being treated with oral anticoagulation (OAC), including direct oral anticoagulants (DOACs) and vitamin K inhibitors (VKAs).1 It is well known that the increased ...
AF Symposium 2023 Atrial Fibrillation Stroke Left atrial appendage occlusion (LAAO) devices are implanted in the heart and are intended to reduce the risk of thromboembolism from the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation. AF Symposium is ...
In recent years, patients undergoing non-emergent percutaneous coronary intervention (PCI) procedures have become increasingly older, with a more significant comorbidity burden and complex coronary disease.1 Many of the patients who undergo elective or urgent PCI are surgical turndown patients, for ...
The COVID-PACT study focused on critically ill patients with coronavirus disease 2019 (COVID-19), assessing the use of antithrombotic therapy. In this touchCARDIO interview, we speak with Dr David Berg (Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA) to discuss ...
Coronavirus disease 2019 (COVID-19) is caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2). Increased risk of thrombotic events is seen in patients infected with SARS-CoV-2, which is higher in patients needing critical care. In this touchCARDIO interview, we ...
touchCARDIO spoke to Dr Duk-Woo Park (Asan Medical Center, Seoul, South Korea) to discuss his presentation at the American College of Cardiology Annual Meeting 2022, providing the results of the ADAPT-TAVR trial of edoxaban versus dual antiplatelet therapy for valve thrombosis ...
Roughly two decades ago, drug-eluting stents (DES) replaced bare metal stents as the most popular stent type used during percutaneous coronary intervention (PCI).1–3 However, soon after the introduction of these early-generation DES, their use was linked to an alarmingly high ...
Coronavirus disease 2019 (COVID-19) has been associated with significant risk of thromboembolic events, particularly among hospitalized patients with elevated D-dimer levels.1–2 Recently, the COVID-19 Registry (CORE-19) study found that discharge anticoagulants were associated with a substantial decrease in the risk of ...
Welcome to the summer 2021 edition of Heart International. This issue contains 9 informative review articles on a range of topics which we hope will be of interest to all cardiovascular practitioners, regardless of subspecialism. We begin with a review by Chu ...
Peripheral artery disease (PAD) is a severe manifestation of systemic atherosclerotic disease that commonly refers to lower-extremity arterial involvement. The global burden of PAD is estimated to involve over 200 million patients, with prevalence increasing by 24% over the past decade.1 In ...
Reperfusion of infarct-related artery (IRA) in acute ST-elevation myocardial infarction (STEMI) is the procedure with the most clinical benefit in interventional cardiology. However, in around 50% of patients presenting with STEMI, other significant lesions are present, a finding which is associated ...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
